Patents by Inventor Kjell Olmarker

Kjell Olmarker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition for use in the treatment of intervertebral disc-related pain
    Patent number: 10322098
    Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 18, 2019
    Assignee: STAYBLE THERAPEUTICS AB
    Inventor: Kjell Olmarker
  • Composition for use in the treatment of intervertebral disc-related pain
    Patent number: 10265284
    Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck-pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid and has a pH below 4. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: April 23, 2019
    Assignee: STAYBLE THERAPEUTICS AB
    Inventor: Kjell Olmarker
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF INTERVERTEBRAL DISC HERNIATION
    Publication number: 20190111178
    Abstract: The invention relates to methods and compositions for use in the treatment or prophylaxis of intervertebral disc herniation in a mammal. The composition according to the invention comprises an inhibitor of T-cell activation, said inhibitor being capable of inhibiting CD28-mediated co-stimulation of T-cells. The said inhibitor of T-cell activation is preferably a protein comprising either an exact or a modified version of the extracellular domain of CTLA-4, such as abatacept, belatacept, XPro9523 and/or ASP2408.
    Type: Application
    Filed: April 2, 2017
    Publication date: April 18, 2019
    Inventors: Kjell Olmarker, Daniel Jonsson
  • COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC-RELATED PAIN
    Publication number: 20180280327
    Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Application
    Filed: May 31, 2018
    Publication date: October 4, 2018
    Applicant: STAYBLE THERAPEUTICS AB
    Inventor: Kjell Olmarker
  • Composition for use in the treatment of intervertebral misalignment
    Patent number: 10080729
    Abstract: The present invention relates to intervertebral misalignment, such as scoliosis, spondylolisthesis, vertebral subluxation and vertebral fractures. A composition for use in the treatment of intervertebral misalignment is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 25, 2018
    Assignee: STAYBLE THERAPEUTICS AB
    Inventor: Kjell Olmarker
  • A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC-RELATED PAIN
    Publication number: 20180256525
    Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck-pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid and has a pH below 4. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Application
    Filed: September 12, 2016
    Publication date: September 13, 2018
    Applicant: STAYBLE THERAPEUTICS AB
    Inventor: Kjell OLMARKER
  • COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC-RELATED PAIN
    Publication number: 20180169041
    Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 21, 2018
    Applicant: Stayble Therapeutics AB
    Inventor: Kjell OLMARKER
  • A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL MISALIGNMENT
    Publication number: 20180071234
    Abstract: The present invention relates to intervertebral misalignment, such as scoliosis, spondylolisthesis, vertebral subluxation and vertebral fractures. A composition for use in the treatment of intervertebral misalignment is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 15, 2018
    Applicant: STAYBLE THERAPEUTICS AB
    Inventor: Kjell Olmarker
  • USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUS
    Publication number: 20120244157
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: June 6, 2012
    Publication date: September 27, 2012
    Applicant: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
    Publication number: 20120093816
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: November 14, 2011
    Publication date: April 19, 2012
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
    Patent number: 8057792
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: November 15, 2011
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Methods for reduction of adhesion formation using cytokine inhibitors
    Patent number: 7994116
    Abstract: The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: August 9, 2011
    Assignee: Pharmasurgics In Sweden AB
    Inventor: Kjell Olmarker
  • Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
    Patent number: 7906481
    Abstract: The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorders.
    Type: Grant
    Filed: January 3, 2007
    Date of Patent: March 15, 2011
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • NOVEL USE OF CYTOKINE INHIBITORS
    Publication number: 20100305048
    Abstract: The use of substance that inhibits a pro-inflammatory cytokine, such as TNF or IL-1, for the production of a pharmaceutical composition for improving wound healing is disclosed. Also, a method for improving wound healing wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment is disclosed.
    Type: Application
    Filed: March 3, 2010
    Publication date: December 2, 2010
    Applicant: PHARMASURGICS IN SWEDEN AB
    Inventor: Kjell OLMARKER
  • Soluble cytokine receptors TNF-? blocking antibodies for treating spinal disorders mediated by nucleus pulposus
    Patent number: 7811990
    Abstract: Described herein are methods and compositions for the treatment of spinal disorders mediated by nucleus pulposus. The compositions can include a soluble cytokine receptor and/or a TNF-? blocking antibody.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: October 12, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
    Publication number: 20100150922
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: March 1, 2010
    Publication date: June 17, 2010
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus
    Patent number: 7723357
    Abstract: Described herein are methods and compositions for the treatment of spinal disorders mediated by nucleus pulposus. The compositions can include thalidomide or a thalidomide derivative.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: May 25, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
    Patent number: 7708995
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: May 4, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • NOVEL USE OF CYTOKINE INHIBITORS
    Publication number: 20090149379
    Abstract: The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.
    Type: Application
    Filed: August 14, 2008
    Publication date: June 11, 2009
    Applicant: PHARMASURGICS IN SWEDEN AB
    Inventor: Kjell OLMARKER
  • Use of cytokine inhibitors
    Patent number: 7427589
    Abstract: The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine such as TNF or IL-1, is administered to a patient in need of said treatment.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: September 23, 2008
    Assignee: Pharmasurgics in Sweden AB
    Inventor: Kjell Olmarker